# Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

> **NCT04541706** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 100 (actual)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT04541706
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-27
- **Primary completion:** 2022-07-20
- **Final completion:** 2022-07-20
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2024-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04541706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04541706, "Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04541706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*